In the present study, we show that targeting of allo-HLA-DPB1 alleles by TCR modified T cells is feasible and could result in strong HLA-DPB1-specific reactivity of CD4 and CD8 T cells against human primary AML samples. This evidence concerns the gene CD8A and acute myeloid leukemia.